Buy -Me-αMT Cas 3569-29-7
Buy -Me-αMT Cas 3569-29-7
-Me-αMT (developmental code name MP-809), or 4-Me-AMT, also known as 4-methyl-α-methyltryptamine or as 4,α-dimethyltryptamine (4,α-DMT), is an experimental antidepressant of the tryptamine and α-alkyltryptamine families that was never marketed.[3][4][5][1][6][7] It is closely structurally related to serotonergic psychedelics and entactogens like α-methyltryptamine (αMT) and α-ethyltryptamine (αET).[1]
Use and effects
4-Me-αMT is active at a dose of 20 to 60 mg orally in humans, though described as being an antidepressant rather than a hallucinogen.[1][2] It was found to be effective as an antidepressant in preliminary clinical studies.[3][6] Alexander Shulgin has said that 4-Me-αMT produced some feelings of unreality at 20 mg, as well as skin flushing, muscle tightness, and mydriasis.[2][8] However, he has said that it could not be called a hallucinogen at assessed doses[2] and has listed the hallucinogenic dose as being greater than 60 mg.[9]
Interactions
Pharmacology
Pharmacodynamics
4-Me-αMT partially reverses reserpine-induced behavioral depression in rodents (by up to 60%), but does not produce hyperlocomotion.[6][10] This was the case at a dose of 50 mg/kg, whereas αMT produced clear hyperlocomotion and near-fully reversed reserpine-induced hypoactivity (by 95%) at a dose of 15 mg/kg.[10] Hence, 4-Me-αMT shows reduced antidepressant- and psychostimulant-like potency compared to αMT.[10] It is also less active than αET.[10] The drug is said to have very weak monoamine oxidase inhibition.[3][6]
Chemistry
Analogues
Analogues of 4-methyl-AMT include α-methyltryptamine (AMT), 4-methyl-AET, 4-methyl-DMT, 4-HO-AMT, 4-HO-AET, and RS134-49 (4-methyl-THPI), among others.
History
4-Me-αMT was first described in the scientific literature by 1962.[6] It was investigated as an antidepressant by Sandoz in Canada in the early 1960s, although it was never
Reviews
There are no reviews yet.